Over recent decades, it has become clear that epigenetic abnormalities are involved in the hallmarks of cancer. Histone modifications, such as acetylation, play a crucial role in cancer development and progression, by regulating gene expression, such as for oncogenes or tumor suppressor genes. Therefore, histone deacetylase inhibitors (HDACi) have recently shown efficacy against both hematological and solid cancers. Designed to target histone deacetylases (HDAC), these drugs can modify the expression pattern of numerous genes including those coding for micro-RNAs (miRNA). miRNAs are small non-coding RNAs that regulate gene expression by targeting messenger RNA. Current research has found that miRNAs from a tumor can be investigated in the tumor itself, as well as in patient body fluids. In this review, we summarized current knowledge about HDAC and HDACi in several cancers, and described their impact on miRNA expression. We discuss briefly how circulating miRNAs may be used as biomarkers of HDACi response and used to investigate response to treatment.
Introduction
In recent decades, non-coding RNAs have been described as key regulators of cellular functions and differentiation. This includes long non-coding RNAs with a size above 200 nucleotides (nt) and small non-coding RNAs (under 200 nt) consisting of numerous subtypes. Micro-RNAs (miRNAs) are endogenous small non-coding RNA of about 19 to 22 nucleotides that modulate gene expression through translational repression, or degradation of the target messenger RNA (mRNA) [1] . A single miRNA has the capacity to inhibit numerous different mRNA targets [2] explaining why miRNAs are potent regulators of gene expression. miRNAs are also important regulators since more than 60% of human genes are regulated by them, as demonstrated by Friedman et al. [3] . In cancer, miRNAs can act as tumor suppressors (TS-miR) or oncogenes (oncomiR), depending on their targets. Recent research has found that miRNAs can not only be detected in tissues but also in all body fluids such as blood, saliva, urine, and milk [4] , where they can be used as biomarkers [5] . MicroRNAs harbor attractive features for uses ranging from translation to clinical practices, such as an easy extraction from body fluids, a resistance to molecular degradation by their encapsulation in exosomes, or by their interaction with lipids and proteins, and their easy quantification by different methods including quantitative PCR [6] .
In the following sections, we will discuss how miRNAs are regulated by epigenetic drugs, such as histone deacetylase inhibitors (HDACi) used in cancer. We will also succinctly discuss the use of circulating miRNAs as a predictor of response to epigenetic clinical therapies. 
Cell Cycle
HDACi induced a cell cycle arrest in G0/G1, G1/S or G2/M phase depending on the cancer cell line and on the used HDACi [38] . Induction of expression of the cyclin-dependent kinase (CDK) inhibitor gene CDKN1A, coding for p21, seems to be a major mechanism in the cell cycle arrest effect of HDACi even if other CDK inhibitors genes are induced by these molecules [39] . The protein p53 was described as a regulator of p21 expression through binding to its promotor [40] . However, the induction of p21 following HDACi treatment is independent on p53 status of cells [41] [42] [43] whereas some studies have described an activation of p53 after HDAC inhibition [44, 45] . Other mechanisms could explain this observation such as dephosphorylation of retinoblasma protein (Rb) [46] [47] [48] and inhibition of E2F transcriptional activity [49] .
microRNAs Dysregulated in Cancer
miRNA dysregulation in cancer was first reported in 2002, when miR-15 and miR-16 were identified at 13q14.3, a frequently deleted region in chronic lymphocytic leukemia (CLL), leading to the overexpression of their target, i.e., BCL-2 (B cell lymphoma 2) [82] . Different miRNAs have been then labeled as TS-miR (tumor Suppressor miR) or oncomiR based on the nature of their target mRNAs. OncomiRs can repress expression of protein-coding tumor suppressor genes and are frequently upregulated in cancer, whereas TS-miRs target cancer-promoting genes and are downregulated [83] .
Let-7c is a one of the most described TS-miRs. It belongs to the let-7 family, highly conserved between species [84] . Let-7c is frequently downregulated in cancer, or even deleted since it is located in a region of frequent homozygous deletion [82] . Let-7c targets various oncogenes and cancer related genes such as IL6-R (interleukin-6 receptor) [85] or E2F5 (E2F transcription factor 5) [86] (Table 3 ). Its downregulation is also associated with poor prognosis in non-small cell lung carcinoma (NSCLC) [87] , in colorectal cancer, or in metastatic prostate cancer [88] .
The miR-17-92 cluster highly conserved among species, comprises six miRNAs (miR-17-5p, miR-18a, miR-19a, miR-20a, miR19b-1 and miR-92a-1), that are overexpressed in many human cancers. miR-18a is one of the most expressed of this cluster, and is considered as an oncomiR. It has been found to be upregulated in breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, gastric carcinoma, pancreatic carcinoma, hepatocellular, and colorectal carcinoma [89] . Interestingly the concentration of miR-18a in plasma or serum of patients with cancer is much higher than that of healthy persons [89] . So aberrant expression of miRNA might serve as a biomarker of cancer or to evaluate cancer response to treatment in non-invasive liquid biopsy.
Over these two examples, numerous miRNAs are dysregulated in malignancies and many data are currently available on their expression for diagnostic or prognostic uses (see review [90] ). [99] E2F5: E2F transcription factor 5, CALU: calumenin, ITGB3: integrin beta 3, MAP4K3: mitogen-activated protein kinase kinase kinase kinase 3, IL6-R: Interleukin 6 receptor, EZH2: enhancer of zeste 2 polycomb repressive complex 2 subunit, DVL3: dishevelled segment polarity protein 3, IL8: Interleukin 8, BCL-XL: BCL2-like 1, CDC25A: cell division cycle 25A, MMP11: matrix metallopeptidase 11, PBX3: pre-B-cell leukemia homeobox 3, PBX2: pre-B-cell leukemia homeobox 2, ERCC6: excision repair cross-complementation group 6
miRNA Regulated by Histone Deacetylase Inhibitors
A few years back, there were discrepancies about miRNA expression modifications by HDACi in tumors [100, 101] probably resulting from different parameters such as cell lines and/or concentrations used. Since then, involvement of miRNAs in HDACi effects on tumors have been well documented. In vitro, miRNAs have an important role in HDACi effects such as in colorectal cancer, where it has Cancers 2019, 11, 1530 7 of 22 been demonstrated that vorinostat modulates not less than 275 miRNAs resulting in a myriad of possible targets and pathways affected [102] . Moreover, in some cases, miRNAs modulated by HDACi have been correlated with tumor stage or clinical outcome. In this section, we will describe the main miRNAs involved in HDACi effects on tumors. In the current state of the art, it is challenging to find a link between miRNAs, HDACi and/or a specific cancer or pathways, and so the following section is ordered regarding both HDACi approval and actions of miRNAs involved (namely, TS-miRs and oncomiRs).
FDA-Approved HDACi and miRNAs
As mentioned earlier, only four HDACi have been approved by the FDA, namely: Vorinostat (SAHA), Panobinostat (LBH589), Belinostat (PXD101), and Romidepsin (FK288). Several studies on various tumor models have been led to understand the mechanisms of these molecules and especially, the importance of miRNAs in tumor-suppressive effects of these HDACi (Table 4) .
HDACi-induced TS-miRs. Treatment by HDACi leads to an increase expression of TS-miR from the let-7 family in several models. Similarly, in hepatocellular cancer, in vitro and in vivo treatment with vorinostat or panobinostat triggers let-7b upregulation, leading to the downregulation of BCL-XL, TRAIL (tumor necrosis factor (ligand) superfamily, member 10) or the oncoprotein HMG2A (high mobility group box 3) [103] (Figure 2 ). Other upregulation, induced by vorinostat, of almost all let-7 family members have been reported in ovarian cancer by Balch et al. [104] as well as in renal cancer by Pili et al. [105] . Conversely, studies described downregulation induced by vorinostat of let-7 family members (let-7b, let-7c, let-7f) in other types of tumors such as lung [106] and thyroid cancers [107] . However, these last studies only described miRNAs modification without going further into let-7-related mechanisms and functions. These discrepancies can also be a consequence of the methods used to purify and screen miRNAs. related mechanisms and functions. These discrepancies can also be a consequence of the methods used to purify and screen miRNAs. Another example of TS-miR is the miR-200 family, consisting of five members divided into two clusters, namely, miR-200b, -200a, and -429 (cluster I); and miR-200c and -141 (cluster II). They are often found to be lost in cancers with different pathways involved [108] . This family appears to be linked with HDACi effects especially in breast cancers were two studies described upregulation of miR-200a and miR-200c induced by vorinostat resulting in i) an upregulation of antioxidant pathway Nrf2 and ii) a decrease of proliferation, invasion and migration in tumor cell lines [109, 110] .
Other miRNAs have been described as playing a crucial role in these HDACi-induced modifications depending on cancer type. Panobinostat treatment has lead to increased cell senescence through miR-31 in breast cancer cells [111] . In pancreatic cancer cells, vorinostat induced many modifications of cell phenotype through miR-34a [112] . One of the most common mechanisms described in the literature is the ability by several HDACi to increase apoptosis in various tumor cell lines in a miRNA-dependent manner (leukemia, lymphoma, pancreatic cancer). This mechanism has been explained by a HDACi-induced upregulation of several miRNAs such as miR-15a, miR-16, miR-34a or miR-195 leading to a downregulation of their target mRNAs mainly (but not only) from the BCL-2 family in vitro and in vivo in mice [104, 113, 114] (Figure 2 ). HDACi-induced oncomiR. The role of miR-17~92 cluster members in promoting tumorigenesis has been widely demonstrated and thus, effects of HDACi on these miRNAs has also been evaluated. Even though the oncogenic role of the miR-17~92 cluster has been largely described, the six miRNAs composing this cluster are not equivalent when it comes to promoting tumorigenesis. Consistently, HDACi affect these miRNAs towards repressing the tumor-promoting tendency of this cluster. In the literature, vorinostat mechanisms often seem to rely on miR-17~92 miRNAs. Indeed, in lymphoma, vorinostat decreases miR-17-5p and miR-18 through c-myc, leading to more sensitivity to apoptosis of tumor cells [115] (Figure 2 ). In another hematopoietic cancer, Lepore et al. demonstrated that vorinostat in human leukemia cell lines, leads to increasing apoptosis through repression of BARD-1 (BRCA1 associated RING domain 1) protein. This vorinostat-induced BARD-1 repression was due to the modulation of several miRNAs within the cell including especially, and surprisingly, an cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . [122] Keap1
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cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] let-7b cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] Cell proliferation Vorinostat cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . MICA, MICB Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a these tumor cells by innate immune cells and especially NK cells [118] . Moreo renal cancer, the decreased cell proliferation induced by vorinostat have been of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] miR-15a, miR16, miR29b renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . MCL1, BCL-2
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a these tumor cells by innate immune cells and especially NK cells [118] . Moreo renal cancer, the decreased cell proliferation induced by vorinostat have been of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . BARD-1
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a these tumor cells by innate immune cells and especially NK cells [118] . Moreo renal cancer, the decreased cell proliferation induced by vorinostat have been of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . 26 miR (see article)
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Other HDACi and miRNAs
There are plenty of HDACi that have not yet been approved by the FDA. Some of them are involved in phase III clinical trials such as Valproic acid to treat cervical and ovarian cancers or Tacedinaline for multiple myeloma and lung cancers [124] . Others are in earlier stages but nonetheless, interesting studies have been done to strengthen the close relationship between HDACi effects and miRNA-related mechanisms ( Table 5 ). Table 5 . microRNAs modulated by histone deacetylase inhibitors used in cancer models.
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Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . PDK1, XIAP, 14-3-3ζ (YWHAZ), cIAP-2 (BIRC3) Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . 
miR-449
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recogn these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorec renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a rep of the miR-17~92 cluster expression [119, 120] . x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . 
miR-889
MICB
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . 
GATA-1
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . [140] Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recogn these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorec renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a rep of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . miR-15a, miR-16, miR-222 (some cells) Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recogn these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorec renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a rep of the miR-17~92 cluster expression [119, 120] . 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein lev these tumor cells by innate immune cells and especially NK cells [118 renal cancer, the decreased cell proliferation induced by vorinostat ha of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] miR-15a, miR-195, let-7a (in vitro and in vivo) of the miR-17~92 cluster expression [119, 120] . BCL-2, BCL-XL Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] miR-34b, miR-132, miR-142-3p, miR-200a, miR-375, miR-489 these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . Proliferation, invasion [141] Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . ↗ miR-373 ↘ LAMP1, VSP4B, IRAK2, BRMS1L, SYDE1, CYBRD1, Associated with poorer disease-free survival [123] miR-9-5p
Cancers 2019, 11, x 9 of 22 cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . CD44 [142] Ovarian AR42
Cancers 2019, 11, x 9 of 22 cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . miR-15a, miR-34, . . .
(see figure in article)
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recogn these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorec renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a rep of the miR-17~92 cluster expression [119, 120] . Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . 
EMT, Canonical Wnt R signaling
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . [122] ↘ let7b, miR-17*, expected targets for each miR listed in the article [106] miR-30d, miR-33, miR-125b
Cancers 2019, 11, x 9 of 22 cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . [123] p53, cyclin B2, CDC25B
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . [122] miR-31
Cancers 2019, 11, x 9 of 22 cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . 
E2F6
Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels these tumor cells by innate immune cells and especially NK cells [118] . renal cancer, the decreased cell proliferation induced by vorinostat have of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . PSA, androgen receptor Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . CIP2A, MYC, 14-3-3z, E6AP, E6, E7 Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better reco these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colo renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a r of the miR-17~92 cluster expression [119, 120] . [143] Cancers 2019, 11, x cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recogn these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorec renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a rep of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . [122] BCL6 (suggested) [144] TSA Cancers 2019, 11, x 9 of 22 cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . MeCP2 [145] NaBu, Sodium Butyrate, E2F: E2F transcription factor, p21/CIP1: cyclin-dependent kinase inhibitor 1A, MET: MET proto-oncogene, receptor tyrosine kinase, BCL-2: B-cell CLL/lymphoma 2, RYBP/DEDAF: RING1 and YY1 binding protein, ZBTB10/RINZF: zinc finger and BTB domain containing 10, HDAC5: histone deacetylase 5, PDK1: pyruvate dehydrogenase kinase, isozyme 1, XIAP: X-linked inhibitor of apoptosis, 14-3-3ζ (YWHAZ): cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition of these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal and renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repression of the miR-17~92 cluster expression [119, 120] . cancer, by vorinostat resulting in an upregulation of MICA protein levels and a better recognition these tumor cells by innate immune cells and especially NK cells [118] . Moreover in colorectal a renal cancer, the decreased cell proliferation induced by vorinostat have been linked to a repress of the miR-17~92 cluster expression [119, 120] . ↘ mRNA levels of c-MYC, E2F1, E2F2 and E2F3 ) of either miRNA or target and their associated pathway.
Firstly, and expectedly, some non-approved HDACi act on similar pathways and miRNA clusters that the ones authorized by the FDA. In lung cancer, the let-7 family miRNAs are also upregulated by TSA, leading to increased cell cycle arrest and apoptosis of tumor cells compared to adjacent non-tumorous lung tissue [125] . Similarly, in lymphoma, let-7a alongside with other miRNAs are upregulated by Romidepsin, decreasing anti-apoptotic proteins such as BCL-2 (B-cell CLL/lymphoma 2) and BCL-XL (BCL2-like 1) [126] . The miR-17~92 cluster members have been described to be regulated by butyrate in colorectal cancer [127] and the miR-200 family is involved in reducing tumor cell proliferation in NSCLC and SCLC (Small Cell Cancer of the Lung) treated with Entinostat (MS275) [128] . miR-34 and miR-15a, described below, are also upregulated by AR42 in ovarian cancer, which trigger a cascade of pathways leading to a decrease of Wnt receptor signaling and EMT (epithelial mesenchymal transition), and an increase of negative regulation processes of cell cycle and apoptosis [104] . The same HDACi in pancreatic cancer, decreases p53 and cyclins protein levels thanks to variation of miR-30d, miR-33, and miR-125b, leading to the inhibition of cell proliferation, invasion and tumor growth, and to an increase of ROS generation, DNA damage and apoptosis [129] . Mocetinostat, a clinical phase II HDACi, has been described as involving miR-31 in the inhibition of E2F6 (E2F transcription factor 6), leading to apoptosis of the prostate tumor cells [130] . Another HDACi, OBP-801, has been described as inducing, both in vitro and in vivo (mice), a decrease of tumor cell growth involving an upregulation of miR-320a [131] . In the same study, they also identified that miR-320a was almost not modified by other HDACi such as SAHA or TSA, highlighting the mechanistic specificities of HDACi.
Clinical Relevance
Interestingly, miRNAs modulated by HDACi have been proven to have importance for clinical outcomes, such as miR-200c and miR-203 in pancreatic adenocarcinomas directly resected from patients. Indeed, the group with no recurrence within six months exerted a much higher level of these two miRNAs than the "recurrence group" [146] . In primary resected tumors, it has been demonstrated that miR-200c and miR-203 may also have a biomarker relevance. Indeed, Hibino et al. showed a significant association between non-recurrence and a high expression of miR-203 and miR-200c [114] . In a clinical study on renal cancer patients, miR-605 was directly targeted by a combination of vorinostat and bevacizumab, an antibody targeting growth factors. They demonstrated that this miRNA was upregulated in treatment responders at baseline and that it was downregulated after treatment ( [105] ; clinical trial NCT00324870). This is explained by the fact that these miRNAs, modified by epigenetic drugs such as HDACi, crosstalk with other proteins such as p53 for instance and are, therefore, able to shift pathways into anti-tumor outcomes for the cell. To further confirm the importance of miRNAs and their relevance in clinics, several ongoing trials plan to investigate miRNA involvement in HDACi-related effects such as Belinostat in carcinoma patients (NCT00926640), or vorinostat in bladder and renal cancers (NCT00926640).
Overall, as previously noticed, it appears difficult to bring out common mechanisms whether it is regarding HDACi molecules, tumor types or miRNAs involved. Conventional clusters such as let-7, miR-17~92, miR-200 are often described to be modified by HDACi but other less studied miRNAs have also been recently described. As expected, effects described are consistent with pathway modifications described in Section 3 of this review. Finally, most of the aforementioned articles have functionally tested miRNAs (mostly with miRNA mimic and/or anti-miR), describing both the importance and the need of these miRNAs to be involved in HDACi-induced mechanisms.
Histone Deacetylase Inhibitors and Circulating miRNAs
As mentioned earlier, miRNAs modulated by HDACi can also be screened in body fluids even if few studies have investigated this characteristic. As a proof of concept, Pili et al. evaluated the modulation of circulating miRNAs in clear-cell renal cell carcinoma (ccRCC) patients under a combinatory treatment of vorinostat and bevacizumab (a humanised monoclonal antibody that neutralises VEGF) [105] . They observed in responder patients an upregulation of miR-20a and miR-let-7b and a downregulation of miR-142-3p, miR-154, miR-605 and miR-199a-5p after treatment. Conversely, miR-605 was upregulated after treatment in progressor patients. Interestingly, this miRNA participates in the p53 network [147] and is frequently upregulated or mutated in cancers [148, 149] .
To our knowledge, this is the only study about the use of circulating miRNAs as a prognostic biomarker of HDACi response, even if it is a conventional approach for other anti-tumor treatments, as recently described in the review of Najminejad et al. [150] and Pardini et al. [151] . We believe however, that it can be a promising approach since miRNAs are stable and easily detectable in all body fluids. Indeed, circulating miRNA are protected from RNase activity through their conjugation with proteins, their inclusion in lipid or lipoprotein complexes or through their loading in exosomes/microvesicles. Exosomes are small intraluminal vesicles that are 50-150 nm in diameter. They are generated inside multivesicular endosomes (MVB) [152] that fuse with cell membranes and release the vesicles into the extracellular space. Exosomal miRNAs participate in intercellular communication (Figure 3) . Uptake by normal cells of the exosome cargo secreted by cancer cells can affect the behavior of recipient cells in various ways that provide benefits to the tumor. Several studies have described how these exosomal miRNAs, induced or not by treatment, participate in tumor immune escape [153, 154] or drug resistance [155, 156] . modulation of circulating miRNAs in clear-cell renal cell carcinoma (ccRCC) patients under a combinatory treatment of vorinostat and bevacizumab (a humanised monoclonal antibody that neutralises VEGF) [105] . They observed in responder patients an upregulation of miR-20a and miRlet-7b and a downregulation of miR-142-3p, miR-154, miR-605 and miR-199a-5p after treatment. Conversely, miR-605 was upregulated after treatment in progressor patients. Interestingly, this miRNA participates in the p53 network [147] and is frequently upregulated or mutated in cancers [148, 149] . To our knowledge, this is the only study about the use of circulating miRNAs as a prognostic biomarker of HDACi response, even if it is a conventional approach for other anti-tumor treatments, as recently described in the review of Najminejad et al [150] and Pardini et al [151] . We believe however, that it can be a promising approach since miRNAs are stable and easily detectable in all body fluids. Indeed, circulating miRNA are protected from RNase activity through their conjugation with proteins, their inclusion in lipid or lipoprotein complexes or through their loading in exosomes/microvesicles. Exosomes are small intraluminal vesicles that are 50-150 nm in diameter. They are generated inside multivesicular endosomes (MVB) [152] that fuse with cell membranes and release the vesicles into the extracellular space. Exosomal miRNAs participate in intercellular communication (Figure 3) . Uptake by normal cells of the exosome cargo secreted by cancer cells can affect the behavior of recipient cells in various ways that provide benefits to the tumor. Several studies have described how these exosomal miRNAs, induced or not by treatment, participate in tumor immune escape [153, 154] or drug resistance [155, 156] . Figure 3 . miRNA biogenesis pathway. miRNA is transcribed in the nucleus and then cleaved numerous times to conduct to a mature single strand miRNA included in the RISC complex. miRNA may regulate gene expression in the cell but also in other cells by their encapsulation in microvesicles such as exosomes. miRNA may also be disseminated through the bloodstream. MVB: endosomal MultiVesicular bodies, RISC: RNA-induced silencing complex. Figure 3 . miRNA biogenesis pathway. miRNA is transcribed in the nucleus and then cleaved numerous times to conduct to a mature single strand miRNA included in the RISC complex. miRNA may regulate gene expression in the cell but also in other cells by their encapsulation in microvesicles such as exosomes. miRNA may also be disseminated through the bloodstream. MVB: endosomal MultiVesicular bodies, RISC: RNA-induced silencing complex.
Conclusions
Many miRNAs have shown different expression levels in response to HDACi treatment. Some of them can potentiate the anti-tumor response, or on the contrary, decrease it. Since tumor cells release miRNAs through exosomes that can be detected in all body fluids, such as plasma, urine or saliva, analysis of circulating miRNAs in patient liquid biopsies provides promising biomarkers to monitor drugs in patients. However, to date, it is still challenging to accurately identify clinically relevant miRNAs due to the lack of standardization in their extraction or in the conservation of biopsy, which greatly affects the stability of miRNAs.
